NASDAQ · KMTS

Kestra Medical Technologies, Ltd.

$22.82 +$1.76 (+8.36%) 1D After hours

Key Metrics

$1.23B
Market cap
P/E · TTM
$95.13M
Revenue · TTM
−$131.61M
Net income
EPS · TTM $-5.35
Dividend yield
Free cash flow −$116.60M
Beta · 1Y 1.61
EBITDA · TTM −$122.61M
Gross margin 51.4%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 26
    The stock moved +17.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 26
  • Apr 10
    From its Feb 11 high, the share price fell 36%.

    Peak close $27.85 on Feb 11; trough close $17.87 on Apr 10. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -36%
  • Mar 12
    The stock moved -14.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 12

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$1.23B
Enterprise value$1.01B
Shares outstanding58.6M
52-wk range$14.10 – $30.00
Avg volume · 20D320.9K
Net cash $219.55M
Book value / share$10.56
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About Kestra Medical Technologies, Ltd.
IPO dateMar 6, 2025
Employees443

Kestra Medical Technologies Ltd is a commercial-stage wearable medical device and digital healthcare company focused on connected monitoring, therapeutic intervention, and data-driven clinical insights for cardiovascular disease.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S12.97
P/FCF
EV/EBITDA
EV/Sales10.67
Graham №

Profitability

Gross 51.4%
Operating -138.0%
Net -138.4%
FCF -122.6%
ROE / ROIC -56.6% · -124.3%

Financial Health

Current ratio4.41
Quick ratio
Debt / equity0.16
Debt / EBITDA -0.35
Net cash $219.55M
Working capital$171.99M

Cash Flow · TTM

Operating CF −$81.70M
Capex −$34.89M
Free cash flow −$116.60M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

5 / 9
Middling fundamentals · 5 of 9 signals passing

Altman Z-Score

4.6
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-01-31 · computed by TickerWolf from SEC filings